Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07518043) titled 'A Phase I Clinical Study of HLX18 vs. OPDIVO(R) in Multiple Resected Solid Tumors' on April 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Shanghai Henlius Biotech

Condition: Esophageal and/or Cardia Cancer Melanoma Urothelial Carcinoma (UC)

Intervention: Drug: HLX18

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: June 30, 2026

Target Sample Size: 174

To know more, visit https://clinicalt...